Executive Team

Our senior level management team brings decades of experience in the global health care sector, and have come to this industry with a common goal: To improve the treatment options for Canadian patients by advancing the science of cannabis.


Neil J. Closner – Chief Executive Officer

Neil brings nearly two decades of start-up, technology and health care experience to the MedReleaf team. His entrepreneurial vision and his passion for high quality health care came together most recently as a member of the senior leadership team at Toronto’s Mount Sinai Hospital where he served as Vice President of Business Development. Previously Neil has served as the founder, CEO or on the board of directors for more than half a dozen technology and health care related start-up companies. Neil also sits on the board of directors of Technion Canada. Neil studied economics at the London School of Economics and Political Science in London, England, attained a BA from McGill University and an MBA from the Wharton School at the University of Pennsylvania. Neil is honored to be working with the world-class teams at both MedReleaf and Tikun Olam and is excited to assist in facilitating national access to MedReleaf’s unique and exceptional varieties of medical cannabis.

Dr. Jeremy N. Friedberg, HBSc, PhD – Scientific Advisor

Dr. Friedberg has been involved extensively in both public and private scientific research projects, holds several patents in plant-based gene expression systems and has years of research expertise in the genetics of commercial plant production systems. He has founded several companies and led the development of numerous scientific research initiatives that have garnered international recognition and awards from the Canadian National Scientific Engineering Research Council (NSERC), the United States National Science Foundation (NSF) and the United Nations. In his role at MedReleaf Dr. Friedberg provides a scientific framework for our internal research – and oversees the development of new strains for specific conditions as well as manages third party research sponsored by MedReleaf. He holds an HBSc in Genetics from the University of Western Ontario, and a PhD in Molecular Genetics & Biotechnology from the University of Guelph.

Angelo Fefekos, CTBS, MLT – Quality Assurance

Angelo brings over a decade of exceptional experience in quality assurance and laboratory technology to MedReleaf operations. His outstanding leadership and technical skills were most recently demonstrated in his role as Manager of a team of 40 in the Division of Diagnostic Medical Genetics and Allograft Technologies at Mount Sinai Hospital in Toronto, where he was responsible for the redesign and implementation of all protocols related to recovery, processing, distribution, sterility assurance and surveillance activities for human tissues for transplant at one of Canada’s largest and most respected human tissue banks. As a result, he successfully implemented Canada’s first, hospital-based manufactured and labeled ‘sterile’ human tissue for transplant use. During this time, he also implemented a new staffing project using Six Sigma and lean techniques that increased productivity by 30%. He also implemented a new workflow that significantly increased patient safety, while standardizing processes and policies. Angelo’s knowledge and experience related to accreditation and regulatory requirements in the production of health products, medical laboratory testing and health services is extensive. As well, he is a Member of the College of Medical Laboratory Technologists of Ontario. Through Angelo’s capabilities MedReleaf will maintain industry-leading levels of quality assurance, consistently delivering products that set the medical standard.

Igor Gimelshtein – Chief Financial Officer

Prior to joining MedReleaf, Igor was a Vice President at Birch Hill Equity Partners, Canada’s leading mid-market private equity firm. At Birch Hill, Igor worked on portfolio companies and potential investments to drive significant growth and value creation across a wide range of industries. Igor played a key role in Birch Hill’s investments in Softchoice, Shred-it, DHX Media (formerly Cookie Jar Entertainment), Carmanah Design and Manufacturing, Mastermind Toys, Nealanders International, and TSC Stores. Prior to joining Birch Hill, Igor worked in San Francisco and New York for Union Square Advisors as an investment banker focused on the technology sector. At Union Square he evaluated and executed mergers & acquisitions and financing transactions across the software, internet & digital media, and hardware sectors. Igor is an active philanthropist, spending the majority of his volunteer time working with the executive team and board of directors of the Toronto Foundation on various initiatives. Igor received his HBA (Ivey Scholar) from the Richard Ivey School of Business, Western University.